Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 7/20 | 0.65 |
| ▸ | ICAM1 | P05362 | 7/20 | 0.65 |
| ▸ | ITGAL | P20701 | 7/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | USP7 | Q93009 | 4/20 | 0.54 |
| ▸ | USP47 | Q96K76 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2681866 | 0.87 | USP7 (0.57) | ITGB2ICAM1ITGALUSP7USP47 | |
| SCHEMBL2680976 | 0.85 | USP7 (0.60) | L3MBTL1USP7USP47RAB9A | |
| SCHEMBL5830335 | 0.78 | ITGB2 (1.00) | ITGB2ICAM1ITGALKMT2ALMNA | |
| SCHEMBL5830329 | 0.78 | ITGB2 (0.70) | ITGB2ICAM1ITGALL3MBTL1KMT2A | |
| SCHEMBL2679788 | 0.75 | USP7 (0.74) | USP7USP47 | |
| SCHEMBL5830523 | 0.73 | ITGB2 (0.65) | ITGB2ICAM1ITGALKMT2ARAB9A | |
| SCHEMBL2680694 | 0.72 | USP7 (0.80) | USP7USP47LMNA | |
| SCHEMBL5830529 | 0.72 | ITGB2 (1.00) | ITGB2ICAM1ITGALKMT2ALMNA | |
| SCHEMBL2681153 | 0.72 | USP7 (0.57) | USP7USP47KMT2ARAB9ALMNA | |
| SCHEMBL2680726 | 0.71 | USP7 (1.00) | ITGB2ICAM1ITGALUSP7USP47 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680139-B2 | Anti-neoplastic compounds, compositions and methods | PROGENRA (US) | 2014-03-25 | — | — | US | claimed |
| US-20120114765-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA | 2012-05-10 | — | — | US | claimed |
| US-8680139-B2 | Anti-neoplastic compounds, compositions and methods | PROGENRA (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120114765-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA | 2012-05-10 | — | — | US | disclosed |
| WO-2010114881-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA INC. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114765-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | SERPINB1, TP53, CTSE | ITGB2 3427/4885ICAM1 4205/4885ITGAL 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.